Last edition
News about "glucosylceramide synthase inhibitor "
FDA Grants Priority Review to Sanofi's Venglustat for Type 3 Gaucher Disease
Sanofi’s brain-penetrant investigational therapy venglustat has received FDA priority review after phase 3 data demonstrated positive efficacy and safety outcomes in patients with type 3 Gaucher disease.
Glucosylceramide Synthase Inhibitor | 29/05/2026 | By News Bureau
Edenbridge Pharmaceuticals Picks PANTHERx Rare for Distribution of Yargesa
PANTHERx Rare has been chosen by Edenbridge Pharmaceuticals for the distribution of Yargesa (miglustat) capsules.
Glucosylceramide Synthase Inhibitor | 02/04/2024 | By Aishwarya | 539
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy